2014
Sequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor Efficacy
Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, Phipps C, Kopparam J, Oh M, Basu S, Kohandel M, Sengupta S. Sequential Application of a Cytotoxic Nanoparticle and a PI3K Inhibitor Enhances Antitumor Efficacy. Cancer Research 2014, 74: 675-685. PMID: 24121494, PMCID: PMC3946433, DOI: 10.1158/0008-5472.can-12-3783.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsBreast NeoplasmsCell Line, TumorCell SurvivalCisplatinErbB ReceptorsFemaleHumansMiceModels, BiologicalNanoparticlesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsProto-Oncogene Proteins c-aktReproducibility of ResultsSignal TransductionConceptsMolecular targeted therapeuticsEnhanced antitumor efficacyAntitumor efficacyBreast cancerCytotoxic agents to tumorsPharmacological inhibitor of PI3KImpact of drug sequencingCombination of nanomedicineAgents to tumorsBreast cancer cellsPI3K) pathwayManagement of cancerInhibitor of PI3KCytotoxic nanoparticlesCombination therapyDrug sequenceOncogenic driversAntitumor outcomesProsurvival signalingCancer cellsPharmacological inhibitorsCancer chemotherapyInduce apoptosisCancerIn vivo validation
2012
Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy
Paraskar A, Soni S, Roy B, Papa A, Sengupta S. Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology 2012, 23: 075103. PMID: 22275055, PMCID: PMC3387556, DOI: 10.1088/0957-4484/23/7/075103.Peer-Reviewed Original ResearchConceptsOxaliplatin in vitroPreferential tumor accumulationReduced systemic toxicityEnhanced antitumor efficacyIncreased antitumor potencyIn vivoBody weight lossEfficacy in vitroNanoscale drug delivery vehiclesMinimal nephrotoxicityAntitumor efficacyNanoparticle administrationTrans-1,2-diaminocyclohexaneSystemic toxicityTumor inhibitionFree oxaliplatinTumor accumulationComplex self-assemblyPlatinum chemotherapeuticsICP-AASOxaliplatinCancer chemotherapyAntitumor potencyCancer chemotherapeuticsMaleic acid copolymers
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply